NVP 0902

Drug Profile

NVP 0902

Alternative Names: NVP-0902

Latest Information Update: 03 Aug 2016

Price : $50

At a glance

  • Originator Navipharm
  • Class Osteoporosis therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoporosis

Most Recent Events

  • 30 Nov 2013 Launched for Osteoporosis in South Korea (unspecified route)
  • 31 Dec 2012 Preregistration for Osteoporosis in South Korea (unspecified route)
  • 31 Dec 2012 Phase-III clinical trials in Osteoporosis in South Korea (unspecified route) prior to December 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top